Ayala Pharmaceuticals Inc (ADXS): ADXS got similar—but slightly better

Reply Private New

Replies (3) Next 10 Prev Next

Send PM Follow Ignore

Followers	839
Posts	120482
Boards Moderated	18
Alias Born	09/05/2002

DewDiligence

Re: fbg0316 post# 37079

Tuesday, 10/03/2017 8:10:43 PM

Tuesday, October 03, 2017 8:10:43 PM

ADXS got similar—but slightly better—financial terms in the NEO deal than CTMX got in the bi-specific-mAb collaboration with AMGN announced today:

http://ir.cytomx.com/phoenix.zhtml?c=254195&p=irol-newsArticle&ID=2304423

Under the terms of the agreement, Amgen and CytomX will co-develop a Probody T-cell engaging bispecific against EGFRxCD3 with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies.

Amgen will make an upfront payment of $40 million and purchase $20 million of CytomX common stock. CytomX will be eligible to receive up to $455 million in development, regulatory and commercial milestones for the EGFR program.

It’s curious how similar the financial terms of the two deals are.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”